Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:ELVN NASDAQ:IMNM NASDAQ:IRON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$10.20+0.1%$11.43$5.90▼$14.51$658.07M1.79834,415 shs102,078 shsELVNEnliven Therapeutics$41.11+2.0%$37.05$14.78▼$48.53$2.50B0.321.18 million shs144,289 shsIMNMImmunome$22.47+1.3%$21.94$7.39▼$27.65$2.54B2.111.38 million shs100,730 shsIRONDisc Medicine$68.21+1.0%$65.03$40.00▼$99.50$2.60B0.93600,266 shs94,736 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-0.68%+2.93%-10.38%-24.41%+53.58%ELVNEnliven Therapeutics-2.21%-2.28%-6.65%+36.95%+120.37%IMNMImmunome-4.64%-3.27%+2.83%-10.81%+198.65%IRONDisc Medicine-1.63%+2.40%+1.02%-15.29%+55.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$10.20+0.1%$11.43$5.90▼$14.51$658.07M1.79834,415 shs102,078 shsELVNEnliven Therapeutics$41.11+2.0%$37.05$14.78▼$48.53$2.50B0.321.18 million shs144,289 shsIMNMImmunome$22.47+1.3%$21.94$7.39▼$27.65$2.54B2.111.38 million shs100,730 shsIRONDisc Medicine$68.21+1.0%$65.03$40.00▼$99.50$2.60B0.93600,266 shs94,736 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-0.68%+2.93%-10.38%-24.41%+53.58%ELVNEnliven Therapeutics-2.21%-2.28%-6.65%+36.95%+120.37%IMNMImmunome-4.64%-3.27%+2.83%-10.81%+198.65%IRONDisc Medicine-1.63%+2.40%+1.02%-15.29%+55.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.38Hold$14.6043.12% UpsideELVNEnliven Therapeutics 2.67Moderate Buy$43.405.57% UpsideIMNMImmunome 2.91Moderate Buy$33.4548.90% UpsideIRONDisc Medicine 2.75Moderate Buy$104.8053.64% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, IMNM, IRON, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026ARVNArvinas CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $24.005/4/2026IMNMImmunome Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/27/2026ARVNArvinas Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026IMNMImmunome Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ELVNEnliven Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026IRONDisc Medicine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026ELVNEnliven Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $56.003/25/2026ELVNEnliven Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$41.00 ➝ $45.003/19/2026ARVNArvinas CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $21.003/19/2026ARVNArvinas BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $16.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$262.60M2.51N/AN/A$6.76 per share1.51ELVNEnliven TherapeuticsN/AN/AN/AN/A$7.74 per shareN/AIMNMImmunome$6.94M366.64N/AN/A$5.75 per share3.91IRONDisc MedicineN/AN/AN/AN/A$18.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$80.80M-$1.28N/AN/AN/A-30.77%-14.25%-9.31%5/12/2026 (Estimated)ELVNEnliven Therapeutics-$103.69M-$1.86N/AN/AN/AN/A-24.22%-23.39%5/13/2026 (Estimated)IMNMImmunome-$212.39M-$2.42N/AN/AN/AN/A-57.61%-52.39%5/11/2026 (Estimated)IRONDisc Medicine-$212.18M-$6.62N/AN/AN/AN/A-36.94%-33.88%N/ALatest ARVN, IMNM, IRON, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ELVNEnliven Therapeutics-$0.44-$0.38+$0.06-$0.38N/AN/A5/12/2026Q1 2026ARVNArvinas-$0.95N/AN/AN/A$16.61 millionN/A5/11/2026Q1 2026IMNMImmunome-$0.60N/AN/AN/A$0.22 millionN/A5/5/2026Q1 2026IRONDisc Medicine-$1.6227-$1.65-$0.0273-$1.65$0.44 millionN/A3/3/2026Q4 2025ELVNEnliven Therapeutics-$0.42-$0.48-$0.06-$0.48$0.01 millionN/A3/3/2026Q4 2025IMNMImmunome-$0.65-$0.75-$0.10-$0.75$0.79 millionN/A2/26/2026Q4 2025IRONDisc Medicine-$1.69-$1.62+$0.07-$1.62$0.15 million($19.88) million2/24/2026Q4 2025ARVNArvinas-$0.55-$1.10-$0.55-$1.10$37.26 million$9.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.924.92ELVNEnliven TherapeuticsN/A28.6628.66IMNMImmunomeN/A14.6914.69IRONDisc Medicine0.0424.0021.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%ELVNEnliven Therapeutics95.08%IMNMImmunome44.58%IRONDisc Medicine83.70%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%ELVNEnliven Therapeutics25.90%IMNMImmunome7.21%IRONDisc Medicine3.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42064.52 million61.47 millionOptionableELVNEnliven Therapeutics5060.90 million45.12 millionOptionableIMNMImmunome40113.25 million105.09 millionOptionableIRONDisc Medicine3038.16 million36.77 millionNot OptionableARVN, IMNM, IRON, and ELVN HeadlinesRecent News About These CompaniesHC Wainwright Cuts Earnings Estimates for Disc Medicine3 hours ago | marketbeat.comIRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsMay 7 at 4:19 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRONMay 7 at 10:00 AM | prnewswire.comDisc Medicine FY2030 EPS Forecast Raised by HC WainwrightMay 7 at 8:34 AM | marketbeat.comA Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response LetterMay 6 at 11:32 PM | finance.yahoo.comRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONMay 6 at 2:43 PM | prnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONMay 5 at 5:26 PM | newsfilecorp.comNDisc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPSMay 5 at 11:46 AM | marketbeat.comDisc Medicine Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 5 at 8:30 AM | globenewswire.comDisc Medicine (IRON) Projected to Post Quarterly Earnings on ThursdayMay 5 at 4:08 AM | americanbankingnews.comIRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsMay 4, 2026 | globenewswire.comROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONMay 3, 2026 | newsfilecorp.comNDisc Medicine, Inc. $IRON Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbHMay 2, 2026 | marketbeat.comJennison Associates LLC Takes Position in Disc Medicine, Inc. $IRONMay 2, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRONApril 30, 2026 | prnewswire.comRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONApril 30, 2026 | prnewswire.comPictet Asset Management Holding SA Grows Stock Holdings in Disc Medicine, Inc. $IRONApril 30, 2026 | marketbeat.comDisc Medicine (IRON) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONApril 29, 2026 | newsfilecorp.comNINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRONApril 28, 2026 | globenewswire.comIRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsApril 28, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesPipelines and Automation: 2 Energy Plays Built for Any Oil PriceBy Chris Markoch | April 26, 2026TPG Built a Record Year, Then Lost 40%—Is the Selloff Overdone? By Peter Frank | April 16, 2026Alcoa Dips After Q1 Miss, But Higher Aluminum Prices LoomBy Thomas Hughes | April 18, 2026Rust to Riches: The Great Resource Realignment By Jeffrey Neal Johnson | April 9, 20263 REITs to Watch as AI Data Center Spending Surpasses Office ConstructionBy Jessica Mitacek | May 7, 2026ARVN, IMNM, IRON, and ELVN Company DescriptionsArvinas NASDAQ:ARVN$10.20 +0.01 (+0.11%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Enliven Therapeutics NASDAQ:ELVN$41.11 +0.82 (+2.04%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Immunome NASDAQ:IMNM$22.47 +0.28 (+1.25%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Disc Medicine NASDAQ:IRON$68.21 +0.68 (+1.01%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
